Adcetris as Consolidation Therapy After Stem Cell Transplant in HL

Seattle Genetics, along with partner Takeda Pharmaceutical Company Ltd., is announcing positive top-line data from the randomized phase III AETHERA study on Adcetris as consolidation therapy following an autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma.

Consolidation therapy targets cancer cells that may remain after initial treatment.

The phase III AETHERA study compared single-agent Adcetris to placebo in 329 Hodgkin lymphoma patients at high risk of relapse. The primary 'endpoint' (something that can be objectively measured) of the study was progression-free survival (PFS).

Call

According to the results, compared to placebo patients given Adcetris in the consolidation setting had a 75 percent improvement in PFS. Seattle Genetics administered Adcetris to those patients in the placebo arm of the study when their disease showed progression.

The company will consider this trial from the endpoint of overall survival in 2016, but before then they will present detailed versions of this data at the annual meeting of the American Society of Hematology (ASH) in December 2014. They will likely submit a supplemental biologics license application (BLA) to the FDA for Adcetris for this indication in 2015.

Adcetris is also being evaluated in three other phase III studies: ALCANZA (relapsed cutaneous T-cell lymphoma (CTCL); ECHELON-1 (front-line advanced classical Hodgkin lymphoma) and ECHELON-2 (front-line CD30-positive MTCL, including systemic anaplastic large cell lymphoma (sALCL).

Source: Zacks

Call

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...